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Introduction
Each of us, in some way or another, is
a beneficiary of research. We all benefit
because advances in knowledge allow health
care professionals to better prevent, manage,
and/or cure various causes of sickness and
disability and to help maintain or improve
quality of life. Health care and human service
professionals benefit in that biomedical and
behavioral research findings add to their
available arsenal of weapons in the fight
against sickness and disability. Planners,
administrators, and consumers of health care
financing and delivery systems benefit from
the lessons, both positive and negative, taught
by health services research. Researchers
themselves, as well as their sponsors, have
important career and pecuniary interests--in
addition to altruistic motivations--in the
conduct and outcomes of research.
Older persons and their families and
formal caregivers, especially those who
require various forms of long-term care
(LTC), have a particularly vital stake in the
research enterprise, because (among other
things) many forms of sickness and disability
are age-related. More effective and affordable
diagnostic and therapeutic interventions for
the horrors of Alzheimer’s disease,
Parkinson’s, heart disease, cancer, and other
illnesses that today disproportionately ravage
the elderly can only be developed and
disseminated if vigorous research efforts about
the medical problems themselves, and
organizational approaches to dealing with
them, are encouraged and facilitated.
Not only do research projects aimed at
the problems of old age usually need the
participation of older human subjects,
but–depending on the research question
being studied--many of those older
subjects may be receiving care in LTC
settings and are especially vulnerable due
to significant mental and/or physical
impa irm ents  such  as de m entia ,
depression, or psycho sis  (Dunn,
Lindamer, Palmer, Schneiderman, & Jeste,
2001) that severely limit or negate their
capacity to make voluntary and informed
decisions about participation in research.
Unfortunately, however, the conduct
of research is almost never an unalloyed good
for older persons or others. Most of the
research projects likely to benefit older
persons and those who care for, and about,
them necessarily involve the use of older
persons as subjects or participants whose
primary role it is to produce the data from
which the researcher may draw generalizable
conclusions that may benefit others in the
future. However, producing such data entails
risks for the research participant. Not only do
research projects aimed at the problems of old
age usually need the participation of older
human subjects, but–depending on the
research question being studied–many of
those older subjects may be receiving care in
LTC settings and are especially vulnerable due
to significant mental and/or physical
impairments such as dementia, depression, or
psychosis (Dunn, Lindamer, Palmer,
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Schneiderman, & Jeste, 2001) that severely
limit or negate their capacity to make
voluntary and informed decisions about
participation in research. An example would
be research attempting to measure the
perceptions that cognitively impaired nursing
home residents have about their quality of life
(Uman, Hocevar, Urman, Young, Hirsch, &
Kohler, 2000).
We have, thus, a Catch-22 situation.
On one hand, there is a scientific and ethical
imperative to conduct biomedical, behavioral,
and health services research on problems
pertaining to older persons in order to
eventually enhance the length and quality of
older persons’ lives. At the same time,
however, we are unable to conduct such
research without the participation of large
numbers of older, frequently extremely
disadvantaged and dependent human
participants both inside (Franzi & Weiler,
1992) and outside of institutional settings.
From this caldron emerge a number of
perplexing legal and ethical questions about
such fundamental matters as the ability to
obtain truly voluntary and competent informed
consent, the proper role of surrogate decision
making in the research context, equitable
selection of research subjects, a fair balancing
of risks and benefits, confidentiality
protections, and payment responsibility for
participation and injury within a protocol
(Karlawish & Casarett, 2001).
There has been a substantial amount of
activity over the past several years, and
continues to be substantial activity, addressed
at the challenge of (a) protecting the rights and
well-being of vulnerable human participants
in various kinds of biomedical, behavioral,
and health services research protocols, on one
hand, without (b) unduly impeding the
conduct of research that promises findings that
may substantially improve health and the
quality of life for many beneficiaries of
research, on the other. Many of the emerging
recommendations for improved participant
protection are relevant to, and in many cases
specifically targeted at, vulnerable older
persons, including long term, chronically
dependent residents of nursing homes or
assisted living facilities, as well as recipients
of home care. This population of older adults
with functional disabilities who may be
approached by investigators to participate in
research protocols is growing.
Yet, both current federal law and
emerging policy recom mendations
defer–usually without any meaningful
elucidation or elaboration–some very
important matters about research
participation, especially regarding
informed consent, determinations of
decisional capacity, and surrogate
decision making authority, to the law of
individual states and the discretion of
individual Institutional Review Boards
(IRBs). 
Thus far, the largest share of the
discussion and recommendations regarding
human research participant protection pertain
to possible legal and policy changes at the
federal level. Yet, both current federal law and
emerging policy recommendations
defer–usually without any meaningful
elucidation or elaboration–some very
important matters about research participation,
especially regarding informed consent,
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determinations of decisional capacity, and
surrogate decision making authority, to the
law of individual states and the discretion of
individual Institutional Review Boards (IRBs).
Applicable law regarding these particular
issues is, and traditionally has been,
determined by the separate states as a matter
of statute, regulation, or judicial precedent.
The role of specific state legislative,
administrative (i.e., regulatory), and common
(i.e., judge-made precedent) law and public
policy in protecting older LTC consumers who
are or may become participants in research
studies thus is a vital topic, but one which has
received a surprisingly small amount of
analysis to date. This report focuses on the
state role, concentrating on Ohio, but
concerning issues of importance nationally.
Ideally, the public policy recommendations
contained herein will serve Ohio’s LTC
research agenda by contributing to the
qualitative improvement of LTC research
conducted in Ohio (including long-term care
research conducted by the State itself),
enhancement of the public’s confidence in the
research process, and protection of the rights
and well-being of Ohio citizens who are
recipients of or candidates for LTC services
and who may be solicited to enroll in research
studies.
The author relied on a variety of
informational sources in formulating the
analysis and recommendations contained in
this report. Research included: a
comprehensive review of the pertinent health
care, legal, and bioethical literature; analysis
of reports by public and private agencies that
recommend legal and policy changes at the
national level; a thorough identification and
examination of relevant state statutes,
regulations, and case law in Ohio and
elsewhere using the Westlaw and Lexis/Nexis
databases; a mail survey of IRBs in Ohio
asking qualitative questions regarding present
protections (and their perceived effectiveness)
for older research participants, especially
those who are recipients of or candidates for
long-term care services; telephone interviews
with a convenience sample of ten
professionals drawn from academia and
private firms who conduct LTC research
(mainly health services research) activities in
Ohio that enroll older participants; and
telephone interviews with a convenience
sample of twenty national experts about the
state role pertaining to legal and ethical
aspects of research participant protection.
The next part of this report sets out
background information on the history and
content of current federal regulations
governing the conduct of research involving
human participants, as well as a summary of
pertinent criticisms of these regulations. The
following section is a general discussion of
the state role in this sphere, addressing the
justifications for state regulation of research,
providing an overview of current state law,
and reviewing key principles that ought to
guide state policy makers. This discussion is
followed by an exploration of specific issues
and policy options arising in the context of the
state’s role in overseeing the ethical propriety
of biomedical, behavioral, and health services
research generally, and especially the conduct
of research involving older and disabled
persons who are recipients of LTC. Finally,
the author outlines potential non-
governmental strategies for achieving desired
objectives in this realm.
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Federal Regulation of Human Subjects
Research
History and General Provisions
 The historical developments leading
up to the current state of federal command and
control regulation of biomedical, behavioral,
and health services research involving human
subjects in the United States have been amply
chronicled (Jonsen, 1998; Rothman, 1991;
Wolpe, Moreno, & Caplan, 1999). Beginning
with the Nuremberg Code, adopted in 1947
for use in Nazi war crimes trials in which
defendant physicians tried to justify their
inhumane treatment of human beings under
the guise of scientific experimentation (Annas
& Grodin, 1992), principles determining the
proper conduct of human experimentation
have been formalized into more than thirty
different international guidelines and ethical
codes (Brody, 1998).
In the U.S., federal government
involvement in the regulation of research
began in earnest in 1966. Officials at the U.S.
Public Health Service (PHS) became
concerned about the increasing frequency with
which human subjects were being used in
research. Formulation of a formal PHS policy
was initiated, and the resulting guidelines
were released in May of 1969. These
guidelines served as a model for the
development of a Department of Health,
Education, and Welfare (DHEW) (now
Department of Health and Human Services
(DHHS))-wide policy announced in April of
1971. This policy retained the institutional
review process initiated by PHS; that is, the
administrative review machinery was adjusted
to cope with the rising tide of research being
conducted with human subjects by switching
from the prior centrally conducted, grant-by-
grant review procedure to a model of
individual institutional responsibility for
compliance with ethical standards. The
DHEW policy also included more specific
requirements for obtaining informed consent
than did the earlier PHS guidelines.
In 1974, the DHEW policy was
translated into enforceable regulations. These
regulations formalized IRBs by withholding
DHEW financial research support from those
institutions that had not established an
organizational review committee that was
scrutinized and approved by DHEW. It
became incumbent on these internal review
committees to provide both general and
special assurances of subject protection, as
well as documentation of informed consent.
The next significant step was
Congressional enactment of Public Law No.
93-348 on July 12, 1974. This statute,
commonly known as the National Research
Act, established the National Commission for
the Protection of Human Subjects in
Biomedical and Behavioral Research (the
Belmont Commission). This body was
charged to (1) conduct a comprehensive study
to identify the basic ethical principles that
should underlie the conduct of biomedical and
behavioral research involving human subjects
and (2) recommend research guidelines and
administrative actions for the implementation
of those guidelines. The accelerating public
concern with the protection of subjects
thought to be at special risk can be seen in
Congress’ specific directive to the
Commission to investigate the ethics of
research on, among other enumerated groups,
the institutionalized mentally infirm
(delineated as those “mentally retarded,
emotionally disturbed, psychotic, or senile”
persons who reside as patients in health care
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institutions). After an extensive series of
hearings, meetings, and deliberations, the
Commission issued a series of reports and
recommendations between 1975 and 1977.
The Belmont Commission followed
the thrust of earlier federal pronouncements by
recommending: (1) that all research involving
human subjects conducted at an institution
that receives federal funding be reviewed by
an IRB before the research is begun, and (2)
that there be prior informed consent by the
subjects involved. Final regulations resulting
from these recommendations were issued on
January 26, 1981, became effective on July 27
of that year, and are codified at 45 Code of
Federal Regulations, Part 46.
These regulations originally applied on
their face only to research involving human
participants that was conducted by the DHHS
itself or that was funded in whole or part by
DHHS. However, most institutions engaged in
human participants research agree to comply
with the regulatory requirements for all of
their research protocols, regardless of the
funding source for any particular study.
Additionally, other federal agencies have
adopted a Common Rule for human subjects
protection in any research study that they
sponsor.1 Research involving the testing of
investigational drugs or medical devices is
concurrently regulated by the federal Food and
Drug Administration (FDA)2 (Merrill, 1997).
The Common Rule and FDA requirements
overlap considerably with each other, but are
not identical.
As defined in federal regulations,
“research means a systematic investigation
designed to develop or contribute to
generalizable knowledge.”3 Thus, research is
different from usual diagnostic and therapeutic
health care or human services delivery, the
latter consisting of interventions that are
designed and expected solely to enhance the
well-being of an individual patient/client and
that have a reasonable expectation of success.
The Institutional Review Board (IRB) Role
Research to which the federal
Common Rule applies must be reviewed and
approved by an IRB and is thereafter subject
to continuing IRB review (Putney & Gruskin,
2002). IRB approval is necessary initially and
at least annually afterwards (Wichman, 1998).
In order to approve a protocol, the IRB must
determine that each of the following
requirements is satisfied:
C Physical and psychological risks to
participants will be minimized
C Physical and psychological risks to
participants are reasonable in relation to
anticipated benefits to those participants
and to the importance of the general
knowledge that may reasonably be
expected to result. This is arguably, and
intentionally, an exercise in paternalism,
the IRB deciding for individuals what is in
their best interests.
C Selection of participants is equitable
C Informed consent will be obtained
145 Code of Federal Regulations Part 46,
subpart A. Pertinent portions of the Common Rule are
reprinted in Appendix 2 . 
221 Code of Federal Regulations §§50.10-40
& 56.101-121. 345 Code of Federal Regulations §46.102(e).
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C Informed consent will be appropriately
documented
C The research plan makes adequate
provisions for monitoring the data
collected to ensure the safety of
participants
C There are adequate provisions to protect
the privacy of participants and maintain
the confidentiality of data
The IRB must police the requirement
that no human participant is involved in
research unless legally effective informed
consent has been obtained and “only under
circumstances that provide the prospective
subject...sufficient opportunity to consider
whether or not to participate and that
minimize the possibility of coercion or undue
influence.” The regulatory provisions for
informed consent in research are basically a
codification and extension of the common law
that was developed in the therapeutic setting
(Faden & Beauchamp, 1986).
Local IRBs themselves are monitored
by the former Office of Protection from
Research Risks (OPRR) (McCarthy, 1995),
which was moved a few years ago from the
National Institutes of Health to the Office of
the Secretary, DHHS (Marwick, 1999) and
renamed the Office for Human Research
Protections (OHRP). OHRP awards the IRB a
Federal-Wide Assurance (FWA) that allows
each IRB to review studies involving human
participants.4
Protecting Decisionally Impaired Persons
The  Be lmont  Commis s ion
recommended in 1978 that, at least for
individuals institutionalized as mentally
infirm, the federal government should
promulgate distinct regulations controlling
research with human participants. Although
proposed regulations were published, these
were never made final (i.e., legally binding).
Among the explanations for this purposeful
inaction, beyond a vague admonition in the
Common Rule that IRBs should be
“particularly cognizant” of the needs of all
vulnerable subjects and should require
“additional safeguards” when such
populations are included in a study,5 are (1)
the objections of the mental health research
community that specially targeted
requirements would be cumbersome and stifle
scientific progress and (2) acceleration of the
trend toward deinstitutionalization of the
mentally ill and developmentally disabled in
the late 1970s and into the 1980s (Childress,
1998).
Neither has action been taken in
response to subsequent calls for specific
research regulations targeting the decisionally
impaired. Recommendations in this vein have
emanated from, among other sources, a
National Institute on Aging (NIA)-sponsored
study group that convened in the early 1980s
to discuss the use of demented persons in
research (Melnick & Dubler, 1985; Melnick,
Dubler, Weisbard, & Butler, 1984) and the
President’s Commission for the Study of
Ethical Problems in Medicine and Biomedical
and Behavioral Research (1983).
4Information on FWAs is available at
<http:// osophs. dhhs. gov/ humansubjects/
assurance/fwas.
545 Code of Federal Regulations
§46.111(b).
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More recently, however, special
protections for the decisionally impaired,
within both institutional and community
settings, have become a renewed item of
interest (Dresser, 2001a; Fleischman, 2001;
Moreno, 1998; Levine, 1996). The national
Alzheimer’s Association (1997) has called
“upon state and federal authorities to clarify
existing laws and regulations as they relate to
people with cognitive impairments.” The
American Geriatrics Society Ethics
Committee (1998, p. 1309) has enunciated the
position:
Federal and state authorities
should clarify existing laws and
regulations as they relate to
research on dementia, especially
regarding the use of advance
directives for research and the
status of proxy consent for
research in the absence of advance
directives. If necessary, pertinent
laws and regulations should be
amended to facilitate important
research on dementia... 
Among the various organizations that
have developed and adopted relevant research
guidelines in this sphere are the American
College of Physicians (1989), the Council for
International Organizations of Medical
Sciences (in collaboration with the World
Health Organization) (1993), Council of
Europe (de Wachter, 1997), and the British
Medical Research Council (1991).  The
American Psychiatric Association organized a
work group for the purpose of formulating
ethical guidelines for psychiatric researchers
dealing with the decisionally impaired.
Several scholars, laboring individually and
within groups, also have weighed in with
comprehensive policy proposals in the area
(Dresser, 1996; High, Whitehouse, Post, &
Berg, 1994; Keyserlingk, Glass, Kogan, &
Gauthier, 1995).
On December 2-3, 1997, the National
Institutes of Health sponsored an Inter-
Institute Conference on Research Involving
Individuals With Questionable Capacity to
Consent: Ethical Issues and Practical
Considerations for IRBs, and subsequently
published a document from that Conference
(National Institutes of Health, 2001). The
latest significant foray into this arena was
launched with the release of the National
Bioethics Advisory Commission (NBAC)
(1998) report entitled “Research Involving
Persons With Mental Disorders That May
Affect Decisionmaking Capacity.”
General Criticisms of the Current Regulatory
Structure
In addition to the critiques and
activities described above directed specifically
at the present vulnerability of research
participants with impaired decisional capacity,
over the last several years there have been a
number of broader criticisms leveled at the
current regulatory system. On June 11, 1998,
the DHHS’s Office of Inspector General
(OIG) issued four reports on human subjects
research and IRBs (U.S. Department of Health
and Human Services, 1998a; 1998b; 1998c;
1998d). Among the concerns noted in these
reports were: overburdened IRBs with
insufficient time and resources to properly
conduct initial and (especially) continuing
reviews; ineffective monitoring of and
response to adverse events happening to
participants; insufficient ethics training for
researchers and IRB members; inadequate
attention to evaluation of IRB effectiveness;
and conflicts of interest involving IRBs and
the institutions of which they are a part,
especially as research funds become more
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scarce. Also in June of 1998, the National
Institutes of Health Office of Extramural
Research released a contractor’s report (James
Bell Associates, 1998) that, although
considerably less critical than the OIG reports,
concluded that protection of human
participants could be improved by fine-tuning
IRB procedures and providing increased
education and training to researchers as well
as to IRB members and staff. The OIG and
NIH reports were accompanied by well-
publicized Congressional hearings before the
Subcommittee on Human Resources of the
House Committee on Government Reform
and Oversight. In April of 2000, the OIG
issued a report (U.S. Department of Health
and Human Services, 2000) finding that,
although the topic of protecting human
research participants continues to receive
substantial public attention, few of the OIG’s
specific 1998 recommendations had been
implemented.
In 1999, the National Institute of
Mental Health (NIMH) announced creation of
a new review panel to screen high risk
intramural and extramural studies funded by
the Institute. That review panel and other
NIMH initiatives were driven “by a desire to
make sure that the science in NIMH studies is
good enough to justify the use of human
subjects” (Marshall, 1999). Typically, IRBs
have essentially taken a hands-off approach to
review of the scientific merits of research
protocols, ignoring the logical link between
the quality of the science and the justification
for allowing any risk to volunteers.
In 2001, the Institute of Medicine of
the National Academy of Sciences issued a
report (Institute of Medicine, 2001)
recommending the establishment of a formal
system for accrediting human research
participant protection programs. The
Association for the Accreditation of Human
Research Protection Programs (AAHRPP)
recently released Final Accreditation
Standards and Procedures (2002) to provide
direction to institutional human research
protection programs that seek AAHRPP
accreditation.
Most significantly, in 2001 the NBAC
issued a report (National Bioethics Advisory
Commission, 2001) that recommended a
variety of substantial changes in the way that
legal and ethical oversight of all research
involving human participants is now carried
out. Among the areas in which consideration
of possible federal policy modifications, or at
least further study, were suggested were those
pertaining to: scope and structure of the
oversight system; level of review; education,
certification, and accreditation in research
ethics; assessing and monitoring compliance;
managing conflicts of interest; IRB
membership; guidance for assessing risks and
potential benefits; the handling of minimal
risk protocols; evaluating potential
participants’ vulnerability; the informed
consent process, including waiver and
documentation; protecting privacy and
confidentiality; monitoring of ongoing
research; adverse event reporting; review of
cooperative or multi-site research studies; and
compensation for research-related injuries.
Current Federal Activities
At present, many of the
recommendations of NBAC and other groups
are under active consideration by
Congressional committees (for potential
statutory changes). For example, a hearing
was held by the Senate Committee on Health,
Education, Labor, and Pensions on April 23,
2002 on “Protecting Human Subjects in
Research: Are Current Safeguards Adequate?”
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The federal agencies that sponsor, conduct, or
otherwise regulate research are actively
studying recommended changes in
regulations, policies, or practices. OHRP
launched in early 2002 a voluntary Quality
Improvement (QI) Program intended to help
institutions evaluate and improve the quality
of their human research protection programs.
One area of substantial controversy
(Annas, 2002; Kulynych & Korn, 2002) and
uncertainty that has emerged lately in this
context revolves around regulatory
implementation of the medical privacy
requirements of the Health Insurance
Portability and Accountability Act (HIPAA)
of 1996.6 HIPAA covers all patient-
identifiable health care information in any
form–oral, written, or electronic–maintained
or transmitted by a wide array of covered
entities, including health care providers,
clearinghouses, contractors, subcontractors,
and health coverage plans. Under the HIPAA
statute, patients have the right to inspect,
copy, and amend their health care information,
authorize or refuse to authorize its use, and
receive a formal accounting of how their
information is used. Substantial civil and
criminal penalties may be imposed on covered
entities for permitting unauthorized access to
protected information.
Final Rules implementing the HIPAA
legislation were published by DHHS on
August 14, 2002.7 Among the most important
provisions of those Rules pertaining
specifically to the conduct of research
involving human participants are:
– A n  i n d i v i d u a l ’ s  w r i t t en
“[a]uthorization for the use or disclosure of
protected health information for a research
study may be combined with any other type of
written permission for the same research
study, including another authorization for the
use or disclosure of protected health
information for such research or a consent to
participate in such research.”8 Because this
regulation permits but does not require the
combining of forms, it remains within the
discretion of researchers or IRBs to determine
whether the combining of information
authorization and consent forms for research
would be appropriate for any particular study.
–A covered entity (such as a nursing
home or home care agency) may disclose to
researchers protected health information
without the written authorization of the
individual, or the opportunity for the
individual to agree or object to the use or
disclosure, when the covered entity has been
presented with a written statement that the
IRB reviewing a proposal “has determined
that the alteration or waiver, in whole or in
part, of authorization satisfies the following
criteria:
(A) The use or disclosure of protected
health information involves no more than a
minimal risk to the privacy of individuals,
based on, at least, the presence of the
following elements: 
  
(1) An adequate plan to protect the
identifiers from improper use and disclosure;
(2) An adequate plan to destroy the
identifiers at the earliest opportunity
6Public Law No. 104-191, §262.
767 Federal Register 53181-53273 (August
14, 2002).
845 Code of Federal Regulations §
164.508(b)(3)(i).
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consistent with conduct of the research, unless
there is a health or research justification for
retaining the identifiers or such retention is
otherwise required by law; and
(3) Adequate written assurances
[by the researchers] that the protected health
information will not be reused or disclosed to
any other person or entity, except as required
by law, for authorized oversight of the
research study, or for other research for which
the use or disclosure of protected health
information would be permitted [by these
regulations];
(B) The research could not practicably
be conducted without the waiver or alteration;
and
(C) The research could not practicably
be conducted without access to and use of the
protected health information.”9
–An individual may revoke, in writing,
an authorization for the disclosure of protected
health information at any time, “except to the
extent that the covered entity has taken action
in reliance thereon.”10 In the Preamble to the
HIPAA regulations, DHHS 
[c]larifies that this provision
permits covered entities to
continue using and disclosing
protected health information that
was obtained prior to the time the
individual revoked his or her
authorization, as necessary to
maintain the integrity of the
research study. An individual may
not revoke an authorization to the
extent that the covered entity has
acted in reliance on the
authorization. For research uses
and disclosures, this reliance
exception at § 164.508(b)(5)(i)
permits the continued use and
disclosure of protected health
information already obtained
pursuant to a valid authorization to
the extent necessary to preserve
the integrity of the research study.
For example, the reliance
exception would permit the
continued use and disclosure of
protected health information to
account for a subject’s withdrawal
from the research study, as
necessary to incorporate the
information as part of a marketing
application submitted to the FDA,
to conduct investigations of
scientific misconduct, or to report
adverse events. However, the
reliance exception would not
permit a covered entity to continue
disclosing additional protected
health information to a researcher
or to use for its own research
purposes information not already
gathered at the time an individual
withdraws his or her authorization.
[DHHS] believes that this
clarification of the Rule will
minimize the negative effects on
research caused by participant
withdrawal and will allow for
important continued uses and
disclosures to occur, while
945 Code of Federal Regulations §
164.512(i).
1045 Code of Federal Regulations §
164.508(b)(5)(i).
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maintaining privacy protections
for research subjects.11
–A valid authorization for an
individual’s permission to use or disclose
protected health information must include
“[a]n expiration date or an expiration event
that relates to the individual or the purpose of
the use or disclosure. The statement ‘end of
the research study,’ ‘none,’ or similar
language is sufficient if the authorization is
for a use or disclosure of protected health
information for research, including for the
creation and maintenance of a research
database or research repository.”12  
State Regulation of Human Subjects
Research–General
Despite the extensive federal presence in
regulating research involving the
enrollment of human participants, there
also exists an important role for the
individual states to play in this arena.
 
Despite the extensive federal presence
in regulating research involving the
enrollment of human participants, there also
exists an important role for the individual
states to play in this arena. As stated in a
background paper prepared for NBAC:
[S]tate law is hardly irrelevant to
the research enterprise. First, to
the extent that research is not
subject to federal law, pertinent
state law (if any) becomes the only
legally applicable regulatory
regime. Second, federal law, when
it does apply to research, expressly
preserves any additional state
protections. The Common Rule
contains the following non-
preemption language: “This policy
does not affect any state or local
laws or regulations which may
otherwise be applicable and which
provide additional protections for
human subjects.”13 In addition to
this general provision, the
Common Rule more specifically
recognizes additional state
requirements for informed
consent: “The informed consent
requirements in this policy are not
intended to preempt any applicable
federal, state, or local laws which
require additional information to
be disclosed in order for informed
consent to be legally effective.”14
Identical language appears in the
regulations of the Food and Drug
Administration.15
This policy decision, to preserve a role
for states in the regulation of the research
enterprise, is unsurprising, for the protection
of human subjects may be seen as an
application of the state’s core function,
protecting its citizens against harm. As the
1167 Federal Register 53225 (August 14,
2002).
1245 Code of Federal Regulations §
164.508(c)(1)(v).
1345 Code of Federal Regulations §
46.101(f).
1445 Code of Federal Regulations §
46.116(e).
1521 Code of Federal Regulations §
50.26(c).
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Supreme Court observed many years ago,
“The police power of a state...springs from the
obligation of the state to protect its citizens
and provide for the safety and good order of
society...It is the governmental power of self-
protection and permits reasonable regulation
of rights and property in particulars essential
to the preservation of the community from
injury.”16 (Schwartz, 2001, p. M3) (citations
omitted)
States also have a regulatory interest in
the health research enterprise because they
provide tangible economic support to this
activity in a variety of direct and indirect ways
(Schwartz, 2001, p. M9). This includes, for
example, grant programs to encourage private
research on particular biomedical17 or health
policy (e.g., the Ohio Long-Term Care
Research Project, MEDTAPP program of the
Ohio Department of Jobs and Family
Services) topics of concern, tax abatements
and other economic development incentives
for research enterprises or facilities, and
mandated insurance benefit laws that
encompass clinical trials or other research
interventions.18 States also facilitate research
by allowing cadaver or organ donation for
research purposes.19 State laws regarding the
privacy of personal health records20 also may
influence the conduct of research. Finally,
state agencies themselves routinely conduct
epidemiologic or other public health research.
At present, only a few states
comprehensively regulate research involving
human participants. California,21 Virginia,22
New York,23 and Maryland24 have omnibus
medical research statutes; the New York and
Maryland statutes were enacted following
extensive state task force consideration of the
topic (Hoffmann & Schwartz, 1998; Dresser,
2001a). In general, these state statutes
reinforce the informed consent, institutional
review board, and confidentiality provisions
contained in applicable federal law and extend
those provisions to all research involving
human participants, regardless of sponsor.
Many states restrict the conduct of
research involving particular categories of
potential participants. For example, many
states (including Ohio) have codified a
nursing home residents’ Bill of Rights which,
among other things, specifies “the [resident’s]
right to refuse, without jeopardizing access to
appropriate medical care, to serve as a medical
research subject.”25 Some states expressly
provide similar protections to home health and
hospice patients.
It is against this backdrop that Ohio
and other states must review their proper role
regarding the regulation of LTC research
projects involving the participation of
vulnerable care recipients. States must
16Panhandle Eastern Pipe Line Co. v. State
Highway Commission, 294 U.S. 613 (1935).
17Ohio Revised Code § 183 .24. 
18Ohio Revised Code §§ 1751.85, 3923.68.
19Ohio Revised Code § 2108.10 . 
20Ohio Revised Code § 3721.13(A)(10). 
21Cal. Health & Safety Code §§ 24173-
24176.
22Va. Code §§ 32.1-162.16, 32.1-162.18,
and 32.1-162.19.
23N.Y. Public Health Law §§ 2441-2445.
24Md. Code–Health §§ 13-1601 through
1606.
25Ohio Rev. Code § 3721.13(A)(12).
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consider what additional requirements, if any,
ought to be imposed on LTC researchers in
order to protect the rights and well-being of
potential research participants, while at the
same time not causing more harm than good
by creating or exacerbating unnecessary
barriers that discourage the conduct of
valuable research, especially involving multi-
site, multi-state collaborative protocols.
Individuals who were interviewed for this
project repeatedly expressed reluctance to
advocate for new state regulation regarding
the conduct of LTC research involving human
subjects, stressing that any state activity in this
arena should be carefully thought out to assure
that any incremental benefits, in terms of
protecting participant rights and well-being,
were clearly likely to exceed the financial and
non-financial costs imposed. At the same
time, certain legal and ethical ambiguities in
the current LTC research regulation
environment were consistently identified, and
interviewees indicated that states might
improve the research climate, and hence
facilitate the conduct of more ethically
appropriate LTC research, by clarifying those
ambiguities. A useful review of any expanded
role for state law and policy in this area entails
several specific inquiries, which are addressed
in the next section.
State Regulation of Human Subjects
Research–Specific LTC Issues
Should Research Involving Participants Who
Lack Decisional Capacity Be Permitted?
Under its inherent parens patriae
power to protect persons who are unable to
protect themselves against possible harm
(Kapp, 1995, pp. 51-52), the state has the legal
authority to ban outright the conduct of LTC
research activities involving human
participants who lack the capacity to consent
to their own participation. Thus, the threshold
public policy question is whether the state
ought to exercise that authority. By permitting
research to take place enrolling individuals
without decisional capacity, the state is
making the value judgment that, in particular
research projects, the potential long range
benefits to society may outweigh the
immediate risks to individual study
participants. It is once that judgment has been
made, explicitly or implicitly, that policy
makers must move to a consideration of what
requirements should be imposed on LTC
researchers to protect the interests of potential
and actual human participants while
permitting legitimate research to proceed.
Is There a Need for Comprehensive
Regulatory Coverage of All Protocols?
As noted earlier, current federal
regulations governing the conduct of
biomedical, behavioral, and health services
research do not apply to all research studies.
Certain privately financed studies conducted
outside of academic institutions and medical
centers may completely elude the oversight
imposed by federal law, even if the protocols
involve the participation of human subjects,
although it would be very difficult to
accurately quantify this shortcoming in the
current regulatory system. In states that have
enacted comprehensive human participants
research legislation, the investigators in all
research studies seeking to enroll human
volunteers are explicitly mandated to comply
with the requirements of state law pertaining
to consent, confidentiality, and IRB review,
regardless of the researcher’s professional
affiliation (or lack of affiliation) and funding
source.
The Ohio legislature could consider
enacting legislation that expressly imposes
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consent, confidentiality, and IRB oversight
requirements on all research studies involving
the potential enrollment of human
participants. Such legislation could follow the
model adopted by the Maryland legislature in
2002 when it enacted House Bill 917, which
requires anyone conducting research with
human participants to comply with pertinent
federal regulations on participant protection.
As noted earlier, a number of national
research ethics experts and Ohio long-term
care researchers were interviewed for this
project. Among these individuals, there was
support for legislation like Maryland House
Bill 917 as a worthwhile form of protection
for some vulnerable individuals who may
presently be at risk of exploitation in the
research context. 
Need for Special Protections for LTC
Recipients?
As indicated above, there are no
current federal regulations that provide
specific, additional protections for potential
research participants who are institutionalized
and/or mentally disabled. Arguably, such
individuals are especially vulnerable and
deserve special protections beyond those
afforded by generic federal regulations to all
research participants. By contrast, the federal
regulatory scheme does provide special
protections to children whose enrollment in
research projects is sought, by requiring that
IRBs considering such protocols affirmatively
answer the following questions (among
others) about each protocol before approving
it:26
For research involving greater than
minimal risk but presenting the
prospect of direct benefit to the
individual subjects–
(1) Is the risk justified by the
anticipated benefit to the
participants?
(2) Is the relationship of the
anticipated benefit to the risk at
least as favorable to the
participants as that presented by
available alternative approaches?
For research involving greater than
minimal risk and no prospect of
direct benefit to individual
participants–
(1) Does the risk represent only a
minor increase over minimal risk?
(2) Does the intervention or
procedure present experiences to
participants that are reasonably
commensurate with those inherent
in their actual or expected
medical, dental, psychological,
social, or educational situations?
(3) Is the intervention or procedure
likely to yield generalizable
knowledge about the participants’
disorder or condition which is of
vital importance for the
understanding or amelioration of
the participants’ disorder or
condition?
State legislatures in Ohio and
elsewhere could consider enacting legislation
that would require IRBs to consider some
version of the same inquiries as a prerequisite
to approval of research studies entailing the
enrollment of members of any vulnerable
population, regardless of age (Fleischman,
2001, p. 16). Such legislation would need to
include a workable definition of
“vulnerability.” The definition could be broad,
2645 Code of Federal Regulations Part 483,
Subpart D, § 46.606.
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such as “having some limitation on
autonomy,” with application left to each IRB
on a case-by-case basis, or categorical, such as
(among others) “all institutionalized persons.”
Such legislation also would need to define
clearly what constitutes “minimal risk” and “a
minor increase over minimal risk.” These
definitions would need to be sensitive to the
specific characteristics of LTC settings and
the persons served in them.
 
Is There a Need for Clarification of the
Regulatory Requirements for Assessing
Potential Participants’ Decisional Capacity?
Given the centrality of the informed
consent doctrine, a legally and ethically
challenging set of issues regarding the
assessment of  po tent ia l  human
par ti c ipants’ decisio nal c apa city
frequently arises in the context of
research conducted in the LTC arena. 
Given the centrality of the informed
consent doctrine, a legally and ethically
challenging set of issues regarding the
assessment of potential human participants’
decisional capacity frequently arises in the
context of research conducted in the LTC
arena. A prospective human research
participant must have the mental
capacity–both cognitive and emotional–to
engage in the rational decision making process
necessary for there to be consent to research
participation (Karlawish & Casarett, 2001).
Individuals cannot autonomously,
authentically volunteer to take part in research
if they are not currently able to comprehend
material information about respective risks
and benefits posed by their participation.
Some mentally compromised
individuals lack sufficient decisional capacity
to validly volunteer for research participation
at the time that initial enrollment is requested,
while some who are capable of giving
autonomous consent to participate at the
inception of the protocol may subsequently
become unable to give valid consent to
continue that participation. Importantly,
though, neither old age nor physical or mental
disability per se necessarily equals decisional
incapacity (Kim, Karlawish, & Caine, 2002).
Decisional capacity must be assessed on a
decision-specific rather than a global basis
(American Geriatrics Society, 1998), with a
focus on function rather than clinical
diagnosis. Many persons with diagnoses of
dementia (Rabins, 1998) and other mental
illnesses are nonetheless sufficiently able to
consent for themselves to research
participation if their disability is not too
severe at the time, especially if participation
would involve only a low degree of risk to the
participant. According to the American
Psychiatric Association (1998, p. 1650):
The identification of some degree
of decision-making impairment in
potential subjects need not result
in their automatic exclusion from
research participation. Many
cognitively impaired subjects can
give adequate consents when
additional efforts are made to
educate them about the nature and
c o n s e q u e n c e s  o f  s t u d y
participation.
NBAC (1998) recommended,
consistent with prevailing law, that capable
individuals’ own consent be accepted as
sufficient for enrollment even in studies
entailing greater than minimal risk with no
prospect of direct benefit to the participant.
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We, therefore, must be able to ascertain with
some precision whether an individual ought to
have his or her own autonomous choice about
participation in research honored or,
conversely, whether the researchers, LTC
providers, and IRB should rely on a surrogate
decision maker or an advance directive for
research participation (both discussed below)
for the particular potential participant.
Explicit substantive standards and
procedural requirements concerning the
assessment of an individual’s capacity to
volunteer to participate in a research project,
in Ohio and most other states, are not
specified in statute or regulation. The resulting
legal uncertainty can inhibit and complicate
the conduct of valuable LTC research
involving participants with questionable
decisional capacity; this can have the positive
effect of making the researchers and
collaborating service settings more
(appropriately) cautious about protecting
potential participants’ rights and well-being
(Karlawish & Sachs, 1997, p. 477), but it also
can delay or preclude the production of
valuable research findings. At the same time,
ambiguity about the regulation of capacity
assessment standards and procedures might
embolden some researchers and collaborators
to expose vulnerable LTC clients to
inappropriate risks and affronts to dignity.
The American Psychiatric Association
(1998) has issued guidelines regarding both
standards and procedures for assessing
decisional capacity, and numerous
commentators (Grisso & Appelbaum, 1998;
DeRenzo, Conley, & Love, 1998) have
endorsed development of standardized written
instruments for assessing capacity to decide
about research participation. NBAC did not
advocate regulatory imposition of any
particular substantive standards or procedural
requirements for the assessment of decisional
capacity, but it did recommend (NBAC, 1998)
that IRBs require that, at least for protocols
involving greater than minimal risk, the
investigator explicitly describe to the IRB the
process the investigator intends to use to
assess the decisional capacity of potential
human participants. This recommendation that
IRBs command researchers to explain how
capacity will be evaluated, both at the start of
a protocol and continuously throughout the
duration of the protocol, is echoed by leading
bioethics and legal commentators (Moreno,
Caplan, Wolpe, & the Members of the Project
on Informed Consent, 1998; Bonnie, 1997).
Many of the LTC researchers
interviewed for this project indicated that they
already supply details regarding the
assessment of potential participants with
questionable decisional capacity in the
protocols they submit to IRBs. Some
researchers indicated that they provide this
information on their own initiative, while
others reported that they are required to do so
by funding sources or internal scientific
review committees. Some commentators have
noted their concern about an absence of IRB
oversight regarding identification of who
should be assessing the present (let alone
future) decisional capacity of prospective
subjects and the standards and methods used
to carry out the capacity assessment
(Derrickson, 1997). Nonetheless, some
interviewees indicated that their respective
IRBs require investigators to provide at least
proposed methods of capacity assessment in
their protocols when there is a possibility that
human participants may be compromised in
the ability to consent to enrollment on their
own. When IRBs impose such a requirement,
it generally is limited to protocols entailing
greater than minimal risk (what several
interviewees described operationally as
Protecting Human Participants In Long-Term Care Research: The Role of State Law and Policy
Scripps Gerontology Center Page 17
protocols entailing an intervention more
intrusive than a finger prick). One survey
(Leblang & Kirchner, 1996) documented that
a number (although a minority) of IRBs
already routinely impose that sort of
requirement on investigators.
The majority of LTC researchers
interviewed for this project stated that, even
when IRBs require information in the research
protocol about capacity assessment, ordinarily
a very subjective, non-structured, virtually
“seat-of-the-pants” process conducted by the
investigator is what occurs. As one researcher
in the field of informal caregiving explained,
“[When it comes to assessing the decisional
capacity of potential participants,] You don’t
really know until you get there.” In one study
of nursing home residents’perceptions of their
quality of life, “[t]he major criterion for
inclusion is the ability of residents to
communicate that they know their name.”
(Uman et al., 2000).
Many researchers indicated that, all or
much of the time, they defer to families or the
formal LTC providers to make an initial
determination regarding which potential
participants are capable of making their own
decisions about research participation.
Interviewees indicated that families and
providers generally are willing to perform that
function, since they know the individual best;
on some occasions, though, researchers
indicate being told, “Don’t ask me, ask the
patient.”
Interviewees indicated that some
research sites, especially some nursing homes,
require investigators to always approach the
family first before even conducting an
assessment of the potential research
participant’s capacity to consent personally;
this provider policy was described pejoratively
as “infantilizing” to the older person. The
LTC provider’s role in screening potential
research participants for decisional capacity
sometimes is specified in the research
protocol, while in other situations occurs on a
less formal, ad hoc basis. At least one major
academic medical center IRB presently
requires proxy consent, as well as the
participant’s assent, for every research study
in which nursing home residents will be
involved, on the overbroad, paternalistic
equation of nursing home residence and
decisional incapacity. Besides the negative
implications for older persons’ rights to make
personal decisions, allowing LTC providers a
too expansive role in screening out potential
participants creates the danger of introducing
biased sample selection into studies.
One sub-issue addressed by NBAC
(1998; Capron, 1999) was whether
investigators with research protocols
involving the enrollment of persons with
questionable decisional capacity should be
required to arrange for assessments of
potential participants by evaluators who are
not professionally or financially interested in
the conduct or outcomes of the study. NBAC
advocated the promulgation of a regulation
mandating that, for any human participants
research study involving greater than minimal
risk, there be an independent assessment of
each potential participant’s decisional
capacity. This is consistent with the position
of the National Alliance for the Mentally Ill
(NAMI) (Flynn & Honberg, 1998, p. 185-
186):
In view of potential conflicts of
interest, it is not advisable for
those directly involved in research
to assume the responsibility of
making capacity determinations.
Rather, we believe that someone
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not directly involved in the
research should make capacity
determinations. This, we believe,
will better ensure that such
determinat ions are  made
objectively by outside experts who
do not have direct interests in the
course or outcomes of the research
protocols.
The British Medical Research Council
Working Party on Research on the Mentally
Incapacitated (1991) recommended that the
determination of decisional capacity be made
by the potential participant’s physician if the
physician is not involved in the research
protocol; otherwise, it should be made by an
independent party acceptable to the IRB or its
equivalent. Neither NBAC, NAMI, nor the
British Medical Research Council Working
Party have gone so far as one New York Court
of Appeals decision27 that compelled a formal
judicial assessment of incompetence for every
potential research participant receiving
services in a facility operated or licensed by
the state Office of Mental Health. Under that
ruling, persons adjudicated incompetent were
banned from volunteering, personally or
through any proxy, to participate in any
research project. The negative reaction to the
inhibitory effect of that decision was so severe
that it led the New York State Department of
Health to establish an Advisory Work Group
on Human Subject Research Involving the
Protected Classes, and to accept that body’s
proposal that, with adequate safeguards,
research be allowed involving more than
minimal risk on decisionally incapacitated
participants even in the absence of likely
benefit to the participants themselves.
A few researchers interviewed for this
project who work at major academic medical
centers indicated that, at least for any
randomized clinical trial (RCT) (which
virtually always would involve a greater than
minimal risk of harm to participants), their
institutions require independent assessment of
potential participants’ decisional capacity. In
some institutions, this is done by investigators
at the institution who are not personally
involved or interested in the particular
protocol, i.e., different investigators trade off
this responsibility with each other. In defense
of the feasibility of conducting independent
capacity assessments, some interviewees
asserted that non-physicians could be trained
to administer and interpret assessment
instruments containing standardized questions
aimed at the individual’s understanding,
appreciation, and reasoning abilities.
By contrast, most interviewees for this
project expressed serious reservations about
mandating that independent capacity
evaluations be conducted for potential
research subjects on a routine basis (as
opposed to the IRB having this requirement in
its arsenal to be imposed very selectively in
particular situations involving particularly
vulnerable subjects and significant risks as
compared with likely benefits). Three types of
problems with a routine requirement of
independent capacity assessment for all
potential research participants were noted: the
practical impossibility of eliminating conflicts
of interest on the part of assessors, the amount
of resources that an independent evaluation
r e q u i r em e n t  w o u l d  r e q u i r e  f o r
implementation, and the questionable validity
and reliability of capacity assessments
conducted by independent, isolated strangers.
First, no assessor of potential research
participants’ decisional capacity can truly be
27T.D. v. New York State Office of Mental
Health , 650 N.Y.S.2d 173 (N.Y. App. Div. 1996).
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“independent.” It was observed that the
presence of conflict of interest can never
really be eliminated, since the purportedly
independent evaluator would be paid directly
by the sponsor of the research or the
institution conducting the research, either of
whom has an interest in the conduct and
outcomes of the study. The only solution
would be a totally volunteer system, and it is
highly unlikely that enough qualified
professionals would be willing to conduct
capacity evaluations of this type on a
continuing pro bono basis.
Second, there is a consensus that
requiring independent capacity assessment on
a routine basis would impose unreasonable
costs on the conduct of research. Those
intolerable costs would place an unnecessary
and unjustified barrier on the research
enterprise that is dedicated to producing
results that, ultimately, are expected to benefit
future persons who suffer or are at risk of
suffering from the same ailments as the
research participants. Further, there is doubt
that an adequate cadre of professionals with
the requisite expertise to routinely conduct
credible independent capacity assessments in
the research context would be available to be
hired at any price, especially outside of the
largest academic medical centers.
Third, interviewees noted that the
better an assessor knows the individual whose
capacity needs to be evaluated, the more
accurate the evaluation is likely to be. Hence,
there is a danger that strangers with no prior
connection to the individual, brought in only
for the purpose of conducting “snapshot”
independent evaluations at one point in time,
may be less accurate and reliable assessors
than investigators or clinicians who have had
a chance to get to know the individual whose
capacity is being evaluated. Independent
evaluators, interviewees also argued, might be
more prone than investigators to conduct
global rather than decision-specific capacity
assessments, and therefore might be too ready
to disqualify some persons who actually
possess the capacity to enroll in certain low
risk protocols. These dangers are especially
worrisome in situations of longitudinal (as
opposed to cross-sectional) projects, during
which a participant’s decision-specific
capacity may change. Investigators arguably
would be best situated to continuously
reevaluate a participant’s decisional capacity
over time.
A legislative option that could be
considered in Ohio and other states is the
enactment of a statutory mandate that IRBs in
the state require investigators to specify in the
template of their research protocols, at least
for protocols potentially exposing
questionably capable participants to greater
than minimal risk: (1) that a structured
capacity assessment of each potential
participant will be performed and (2) in detail,
the standards and procedures the investigator
proposes to utilize in assessing the initial and
ongoing decisional capacity of potential
participants. This part of the protocol template
could be structured either by statutorily
requiring IRBs to ask investigators certain
specified questions about capacity assessment
in their application forms, or by requiring
IRBs to develop their own list of questions to
include on their application forms. Either of
those approaches would more likely instill
some uniformity in IRB and investigator
practice than would asking in an open ended
fashion for the investigator’s description of
the proposed capacity assessment process.
Undergoing a formal capacity
assessment may be perceived as burdensome
(indeed, sometimes more burdensome than the
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research study itself) by the potential
participant, especially a person with dementia.
Therefore, regulatory intervention must seek
to minimize the degree of potential burden
imposed in the course of trying to promote the
individual’s interest in autonomy.
Furthermore, a related legislative
option could be a requirement that capacity
assessments for research participation
purposes be conducted, at least for protocols
exposing participants to greater than minimal
risk of harm, by independent evaluators. Any
such requirement should include provisions
minimizing as much as feasible the financial
or academic interest of the independent
evaluator in the outcome of an evaluation.
Such provisions could include, for instance,
prohibiting the amount of the evaluator’s
compensation from being tied to the number
of participants enrolled in the study or even to
whether or not the study was eventually
carried out. 
Clarification of Proxy Decision Making for
Research Purposes?
As stated by one leading legal
commentator:
Once subjects with possible
impairments have been identified,
the IRB should take special
precautions to ensure that valid
consent (or assent) is obtained
(and that it remains valid during
the course of the study). The IRBs
should not be required to use any
single procedure. Instead, the
regulations should provide a menu
of safeguards, and the IRB should
be directed to select the
procedures that provide the best fit
for the particular study, taking into
account the nature and prevalence
of anticipated decision-making
impairments and the degree of risk
presented by the study (Bonnie,
1997, p. 110).
There is a need for clarification of state
law regarding the issues of: (1) who may
act as a decision making proxy for
purposes of enrolling a person in a
research study; (2) the extent and limits
of a proxy decision maker’s authority in
the research context; (3) the standards
that a proxy must use in making
decisions about research participation on
behalf of a decisionally incapacitated
person (Alzheimer’s Association, 1997);
and (4) the liability implications when a
decisionally incapacitated person who
has been enrolled in a research project by
a proxy is injured as a result of
participation in that study.
Part of the menu of protections that
should be enforced by IRBs for research
involving participants with significant
cognitive and/or emotional impairment must
involve reliance on proxies. Proxies may
make decisions about participation either for
the decisionally incapacitated individual or
with the assent of the impaired, but arguably
still minimally capable, individual. However,
in particular research situations the status and
role of the purported proxy may be quite
unclear (American Academy of Neurology
Ethics and Humanities Subcommittee, 1998,
p. 594). There is a need for clarification of
state law regarding the issues of: (1) who may
act as a decision making proxy for purposes of
enrolling a person in a research study; (2) the
extent and limits of a proxy decision maker’s
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authority in the research context; (3) the
standards that a proxy must use in making
decisions about research participation on
behalf of a decisionally incapacitated person
(Alzheimer’s Association, 1997); and (4) the
liability implications when a decisionally
incapacitated person who has been enrolled in
a research project by a proxy is injured as a
result of participation in that study. 
Who May Be a Proxy for Research Purposes?
Many of the LTC researchers
interviewed for this project reported that they
often ask a potential research participant’s
formal or informal LTC provider whether
non-research related (e.g., general health care,
financial) decisions for that particular
individual usually are made by that individual
personally or by a proxy acting on the
individual’s behalf. When the provider’s reply
is that non-research related decisions are made
by a specific proxy, the researchers indicated
that they tend to turn to that same proxy for
decisions about the individual’s participation
in research studies, and that this way of
proceeding ordinarily has been satisfactory to
IRBs that inquire about the role of proxies in
a research project. In some situations,
investigators review the chart maintained by
the LTC provider of a decisionally
questionable potential research participant,
and then turn for consent to the one indicated
in the chart as the “contact person” (Baskin,
Morris, Ahronheim, Meier, & Morrison,
1998). (This practice raises confidentiality
concerns, especially in light of HIPAA,
discussed earlier.) Interviewees reported that,
in practice, they generally paid little attention
to questions about a proxy’s legal authority, if
any, to make research enrollment decisions on
behalf of the incapacitated person. With a few
exceptions, it appears that researchers and
IRBs (LeBlang & Kirchner, 1996) do not
usually restrict their reliance on proxy
decision makers to those who have been
appointed to the proxy role through a durable
power of attorney document or a guardianship
order. This widespread lack of concern about
explicit legal authority in this context appears
to rest, in large part, on a supposition that
most families and LTC providers (especially
mission-driven organizations in the not-for-
profit sector) can be trusted to be acting in the
best interests of incapacitated LTC recipients.
Extent and Limits of Proxy’s Authority?
The common practice regarding
researchers’ reliance on proxy decision
makers for decisionally incapacitated research
participants often may be inconsistent with the
demands of legal theory. According to the
strict letter of the law, a proxy would have
authority to enroll a decisionally incapacitated
individual in a research project only if the
proxy had been given such authority explicitly
in: (a) a durable power of attorney (DPOA)
document executed by the decisionally
incapacitated person earlier while still
retaining decisional capacity; (b) a
guardianship order issued by a court; or (c) a
state statute specifically conferring this
authority. Since Ohio does not have a state
statute specifically conferring such authority
on a proxy, in this state a proxy would have
official legal authority to act in the research
context only through a DPOA or a
guardianship order.
In practice, though, few older LTC
service recipients who currently lack sufficient
decisional capacity to enroll themselves in a
research project have a proxy who possesses
explicit legal authority to consent to
participation on their behalf. DPOAs and
judicially created guardianships are rare. Even
when an individual, while still decisionally
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capable, has executed a DPOA authorizing a
named agent to make health care decisions,
the DPOA statute in most states (including
Ohio)28 is silent on the specific question of the
agent’s authority to make decisions about
participation in research. The Ohio
guardianship statute, like its counterpart in the
majority of other states, is silent on the power
of a guardian to enroll an incompetent adult
ward in research.29
Some interviewees advocated a
requirement that proxies have formal legal
authorization to enroll another person in a
research project, at least when the participant
would be exposed to an unfavorable
risk/direct benefit ratio. Under this approach,
decisionally incapacitated persons who had
not previously executed a DPOA explicitly
giving their agent permission to enroll them in
certain research studies and who had not been
adjudicated incompetent by a court that
expressly authorized a guardian to enroll the
ward in research protocols would effectively
be disenfranchised from participating in
research. A small number of LTC research
sites insist on this “no designated agent or
guardian, no enrollment” approach as a
condition of participating with the
investigator. Such insistence, resulting in the
exclusion of such residents from research
participation, ordinarily is based on perceived
risk management considerations affecting the
LTC providers.
By contrast, the vast majority of LTC
researchers and research ethics experts
interviewed for this project objected
strenuously to any wholesale exclusion of
otherwise eligible participants on the grounds
that they fail to have a DPOA or guardianship
order that speaks explicitly to the proxy’s
power to make decisions in the research
context. Few individuals would satisfy that
qualification. Realistically, this situation is not
going to change, since a huge upsurge in the
execution of timely, formal advance directives
for research participation is unlikely despite
the expressed willingness of many individuals
to participate in future research if they lose the
ability to consent (Wendler, Martinez,
Fairclough, Sunderland, & Emanuel, 2002). It
was contended by interviewees that such
insistence on legal formalism would both deny
many LTC service users the opportunity to
derive the benefits that might be available to
participants in particular research projects and
that it would badly skew or bias the
representativeness of study sample
populations and therefore the validity of study
results. Instead of insistence on legal
formalism, the weight of informed opinion
urges, unless another family member or friend
expresses dissent, continued reliance on study
enrollment through proxies who lack explicit
legal authority but who do not appear to have
their judgment clouded by any serious
conflicts of interest pertaining to the
enrollment decision (American College of
Physicians, 1989; American Geriatrics Society
Ethics Committee, 1998; Flynn & Honberg,
1998; Rabins, 1998). Researchers and ethics
experts afford the greatest presumption of
moral authority to informal proxies who have
a history of making decisions for the
decisionally incapacitated person, who appear
to really know the incapacitated individual,
and who are likely to be good reporters to the
investigator about any adverse reactions of the
participant to the research interventions.
Family members or others acting as caregivers
for decisionally incapacitated persons are
28Ohio Rev. Code § 1337.13.
29Ohio Rev. Code chap. 2111.
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afforded particular deference (Karlawish &
Casarett, 2001).
Moreover, most researchers
–voluntarily or under individual IRB mandate
–place a practical limitation on proxies’
authority to enroll decisionally incapacitated
persons in studies by requiring participants’
assent (affirmative or at least signified by not
objecting) to participation, in addition to the
proxy’s consent. This practice of giving even
decisionally incapacitated persons the
equivalent of a veto power is consistent with
the prevailing ethical  consensus.
Recommendation 7 in the NBAC report
(National Bioethics Advisory Commission,
1998) states, “Any potential or actual subject’s
objection to enrollment or to continued
participation in a research protocol must be
heeded in all circumstances.” According to the
American Geriatrics Society Ethics
Committee (1998, p. 1309), “In general, the
refusal of a (potential) subject, even if that
subject has lost decision-making capacity,
should be followed.” The state legislature
could consider making a potential
participant’s active or passive assent a
requirement for the initial and continuous
involvement of that person in a LTC research
project.
If we are going to continue to rely on
proxies, either de jure (i.e., with formal legal
authority) or de facto, to make decisions about
research study participation generally on
behalf of decisionally incapacitated persons,
are there any explicit legal limits that ought to
be set on the proxy’s de jure or de facto
authority? For example, both the NBAC
report (National Bioethics Advisory
Commission, 1998) and the latest version of
the Declaration of Helsinki (World Medical
Association, 2000) suggest that proxies be
permitted to enroll decisionally incapacitated
persons only in studies that focus on a
condition from which the enrollee suffers,
thus discouraging the enrollment of
incapacitated participants mainly as a matter
of convenience to the investigator. Neither of
these documents, however, advocate for
restricting enrollment solely to studies
involving the possibility of direct benefit to
the decisionally incapacitated person. A
restriction of that sort could impose major
impediments to the conduct of case/control
studies, in which the control (non-
intervention) participants exist solely as a
comparison group, and hence by definition
and design are not going to directly benefit
from their participation in that particular study
(except perhaps through a placebo effect). 
Standards for Proxy Decision Making About
Research?
A person who, with or without the
formal legal authority to do so, is asked for
permission to enroll a decisionally
incapacitated person in a research study
should be given guidance about the standard
to be used in carrying out the proxy decision
making function. The competing standards
available are substituted judgment and best
interests (Dresser, 2001a, p. 677, 687-688).
The substituted judgment standard emphasizes
individual autonomy, by expecting the proxy
to try to stand in the shoes (“don the mental
mantle”) of the decisionally incapacitated
person and make decisions consistent with
that person’s previously expressed or implied
values and preferences–to ask, in essence, If
the person were currently able to decide,
would that person choose to participate in this
research study? Under this approach, the
proxy really speaks, rather than decides, for
the incapacitated person. By contrast, the best
interests standard is predicated on the ethical
principle of beneficence, or doing good for
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others. Under this test, the proxy gets to
decide what he or she thinks is the best choice
for the incapacitated person, based on the
proxy’s own weighing of probable benefits
and burdens to the incapacitated person.
In Ohio, as generally elsewhere, the
statutory, regulatory, and common law are
silent on the question of the standard to be
applied to proxy decision making in the
research context. While Ohio’s DPOA for
health care statute30 requires appointed agents
to act consistent with the substituted judgment
standard when possible and Ohio’s
guardianship statute embodies the traditional
best interests standard, neither of these
statutes speak specifically to proxy decisions
about entering or continuing a decisionally
incapacitated person in a research study.
In practice, proxies often rely on a
combination of the substituted judgment and
best interests standards when making
decisions in the research context, depending
mainly on the extent to which credible
information is available concerning the
pertinent values and wishes of the decisionally
incapacitated person (LeBlang & Kirchner,
1996, p. 533). Nevertheless, state law could
usefully clarify the order of preference among
these two approaches that proxy decision
makers are expected to follow in the research
context.
Liability Implications of Proxy Decision
Making About Research?
If an incapacitated individual is injured
in the course of participating in a LTC
research protocol and the injury resulted from
negligent acts or omissions on the part of the
investigator or study site, the ordinary rules of
tort and/or contract law would apply to resolve
a civil claim for monetary damages brought on
behalf of the injured research participant.
However, the legal status of a civil action
brought on behalf of an injured, decisionally
incapacitated research participant based on the
claim that the proxy lacked valid authority to
consent to participation for the incapacitated
person is unclear. Any state legislation or
regulation dealing with the other aspects of
proxy decision making in the LTC research
context discussed above also should clarify
the liability implications of proxy consent.
Specifically, policy makers need to grapple
with such questions as:
• May a civil action in tort and/or contract
be brought on a decisionally incapacitated
person’s behalf, following a research
participation related injury, alleging lack
of valid consent to research participation
even though a proxy gave voluntary and
informed permission to enroll the
incapacitated person?
• If so, against which party(ies) may such a
lawsuit be brought?
• What defenses, if any, could a defendant
assert against such a lawsuit?
If LTC investigators and study sites do
not feel confident in the legal validity of proxy
consent to research participation (i.e., they
fear being held liable for violating
participants’ informed consent rights despite
the permission of proxies to enroll the
decisionally incapacitated persons, such as
30Ohio Rev. Code § 1337.13.
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recently happened in Maryland),31 they will
not conduct research involving incapacitated
participants. The negative consequences of
categorically excluding incapacitated persons
from participating in LTC research have been
discussed above.
 
Summary of Policy Issues Regarding Proxy
Decision Making
The NBAC report (1998) admonished
the states to clarify their laws on proxy
decision making for research purposes. The
Ohio legislature should consider legislatively
clarifying who is legally authorized to act as a
proxy for a decisionally incapacitated person
in the research context, and under what
conditions. More specifically, the legislature
should consider enacting or amending statutes
that explicitly clarify the following issues:
• whether DPOAs or other forms of advance
directives may be used to delegate power
to an agent to make decisions about a
decisionally incapacitated person’s
research participation (Dresser, 2001a, pp.
673-674; Dresser, 2001b);
• whether a generic DPOA for health care
would suffice for that purpose or a
separate and more specific advance
directive would be necessary (Dresser,
2000; Moreno, Caplan, Wolpe & the
Members of the Project on Informed
Consent, 1998);
• whether a general guardianship of the
person order encompasses the guardian’s
authority to enroll the ward in research
studies or a separate and more specific
judicial order is necessary; 
• who (if anyone), in hierarchical order, has
authority to enroll a decisionally
incapacitated individual in a research
study in the absence of a relevant advance
directive or guardianship order
(considering the enactment of a law
analogous to Ohio’s default proxy
decision maker statute applicable to the
sphere of decisions about life-sustaining
medical treatments for critically ill
persons);32 
• any limits on the authority of a DPOA
agent, guardian, or default proxy regarding
the type of research study in which the
decisionally incapacitated person may be
enrolled through proxy consent; and the
standard(s) that a proxy must use for the
decision making process in the research
context.
• Whether a civil lawsuit for monetary
damages may be brought on behalf of a
decisionally incapacitated research
participant who was injured as a result of
research participation, on the grounds that
proxy consent to research participation
was invalid.
Additionally or alternatively, state law
could compel IRBs to require investigators to
specify in their protocols how they intend to
handle the details of proxy decision making,
without imposing on the investigator any
particular process and criteria for selecting the
proxy and recognizing or limiting the proxy’s
decision making authority. Such a requirement
would allow investigators and IRBs a
31Grimes v. Kennedy Krieger Institute, 366
Md. 29, 782 A.2d 807 (2001), reconsideration denied
(October 11, 2002). 32Ohio Rev. Code § 2133.08.
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substantial degree of flexibility, while forcing
them to devote considerable a priori thought
to the pertinent issues.
   
Non-Governmental Strategies
The focus of this report has been on
the current and potential role of governmental
action, primarily at the state level, regarding
oversight of the conduct of biomedical,
behavioral, and health services research in
LTC settings. As has been explained, the state
has a legitimate interest in protecting the
autonomy, dignity, and well-being of
vulnerable individuals who may be asked to
serve as participants in LTC research; various
possible state initiatives for pursuing this
interest have been outlined.
However, the long-term care
researchers and legal and ethical experts
interviewed for this project generally strongly
urged caution and restraint in implementing
new state laws and policies that might prove
to be unnecessary, unhelpful, and so
burdensome on honest, competent researchers
t h a t  t h e y  h av e  t h e  e f f ec t  o f
counterproductively deterring the conduct of
potentially valuable LTC research. The
interviewees are correct in their assertion that
credible evidence of serious abuses in the LTC
research arena has not yet surfaced. Recent
well-publicized research ethics problems at
major academic medical centers around the
country have involved the alleged
mistreatment of young, relatively healthy
participants in acute care or ambulatory
settings, rather than older, decisionally
incapacitated persons in LTC settings. The
interviewees also consistently and
persuasively argued that any research
regulations, and the IRBs, research sites, and
administrative agencies who are responsible
for applying those regulations in practice,
need to distinguish among protocols based on
risk/benefit ratio considerations. Most of the
interviewees making this point come from the
world of behavioral and social science
research (e.g., chart reviews, observational
studies), where the risks to study participants
are likely to be much less substantial than
those commonly encountered with biomedical
research interventions (Glass & Speyer-
Ofenberg, 1996).
Instead of, or as a supplement to,
aggressive state regulatory actions, a variety of
non-governmental initiatives might be
supported to further society’s responsibility to
protect vulnerable persons without creating
the risk of depriving those same vulnerable
persons of the possible benefits of knowledge
derived through research efforts. Such non-
governmental initiatives might include:
1. The development and dissemination
of consensus guidelines on the ethical conduct
of LTC research using human participants by
panels convened by private organizations,
similar to the way in which private groups
convene consensus development panels to
establish standards or guidelines for the
diagnosis and treatment of various medical
problems.
2. The adoption and enforcement of
privately established ethical research practice
guidelines by foundations and private industry
representatives that fund LTC research, with
expectations and understandings spelled out
clearly in funding applications agreements and
financial support withheld or withdrawn from
investigators when unacceptable deviations
from established private guidelines occur.
3. Professional journals requiring that
important issues pertaining to the ethical
conduct of the research reported be discussed
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either directly in the methodology section of
the submitted article or in a separate form that
is submitted along with the article, akin to
forms currently widely employed for copyright
transfer and declaration of conflicts of interest
(Yank & Rennie, 2002).
4. Better education of investigators,
IRB members, and LTC providers (including
governance, administration, and direct care
staff of institutions and agencies) about both
research ethics and the special characteristics
and needs of the various populations receiving
LTC services. As part of satisfying federally
mandated human subjects protection training,
researchers can learn about the issues of
decisional capacity and proxy decision
making. Special attention should be paid to
developing guidance for LTC providers
regarding a fair process of reviewing
investigators’ requests to allow them to
conduct research enrolling a provider’s
patients/clients, to encourage provider
responses somewhat more thoughtful than
either an automatic “go away” or an automatic
“do anything you want.” Pertinent information
also should be made available to interested
family members of LTC clients, to empower
families to participate and advocate more
effectively regarding decisions about
enrollment of their loved ones in research
projects and in the ongoing monitoring of
those projects.  Although primary
responsibility for planning and conducting
educational activities would best be left to
academic institutions and professional
organizations and agencies, the state could
make a valuable contribution by financially
supporting these educational activities.
5. Training of investigators regarding
the proper conduct of assessments of
decisional capacity of LTC service recipients
for research participation purposes.
In the final analysis, both the
considerable power and the definite limits
of state law and policy in this arena must
be acknowledged. 
In the final analysis, both the
considerable power and the definite limits of
state law and policy in this arena must be
acknowledged. The law at any level can only
guide, facilitate, and reinforce–but never
totally substitute for–the ethical sensitivity and
integrity of research investigators
(Yarborough & Sharp, 2002) and LTC service
providers. A malevolent researcher can always
find a way to evade regulatory mandates.
“One danger of excessive regulations is that
they can actually undermine researchers’ sense
of moral responsibility as their attention shifts
from their obligation to research subjects to
their compliance with the regulations”
(Michels, 1999, p. 1429). In this area as in
many others, the state may serve the public
best if it skillfully combines its traditional
roles of regulator and enforcer with those of
moral educator and partner.
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Appendix 1
Questions for State Policy Makers
1. Should the state permit the conduct of LTC research involving participants who lack decisional
capacity?
2. Should the state impose regulatory requirements on all LTC research involving human
participants, regardless of funding source or investigators’ affiliations?
3. Should the state impose requirements to protect participants in LTC research projects that exceed
the protections required in other research contexts?
4. What requirements, if any, should the state impose on investigators regarding the assessment of
decisional capacity for potential participants in LTC research projects?
5. When investigators seek to enroll decisionally incapacitated persons as participants in LTC
research projects, what requirements should the state impose regarding who may act as a proxy
decision maker for research purposes, the permissible extent and limits of the proxy’s authority
in this context, and standards for proxy decision making about a decisionally incapacitated LTC
recipient’s research participation?
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Appendix 2
Common Rule
CODE OF FEDERAL REGULATIONS
TITLE 45
PUBLIC WELFARE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH
OFFICE FOR PROTECTION FROM RESEARCH RISKS
PART 46
PROTECTION OF HUMAN SUBJECTS
* * *
Revised November 13, 2001
Effective December 13, 2001
* * *
Subpart A --Federal Policy for the Protection of Human Subjects (Basic DHHS Policy for Protection
of Human Research Subjects)Sec.
46.101 To what does this policy apply?
46.102 Definitions.
46.103 Assuring compliance with this policy--research conducted or  supported by any Federal
Department or Agency.
46.104-
46.106 [Reserved]
46.107 IRB membership.
46.108 IRB functions and operations.
46.109 IRB review of research.
46.110 Expedited review procedures for certain kinds of research involving no more than
minimal risk, and for minor changes in approved research.
46.111 Criteria for IRB approval of research.
46.112 Review by institution.
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46.113 Suspension or termination of IRB approval of research.
46.114 Cooperative research.
46.115 IRB records.
46.116 General requirements for informed consent.
46.117 Documentation of informed consent.
46.118 Applications and proposals lacking definite plans for involvement of human subjects.
46.119 Research undertaken without the intention of involving human subjects.
46.120 Evaluation and disposition of applications and proposals for research to be conducted or
supported by a Federal Department or Agency.
46.121 [Reserved]
46.122 Use of Federal funds.
46.123 Early termination of research support: Evaluation of applications and proposals.
46.124 Conditions
Authority: 5 U.S.C. 301; Sec. 474(a), 88 Stat. 352 (42 U.S.C. 2891-3(a)).
Note: As revised, Subpart A of the DHHS regulations incorporates the Common Rule (Federal
Policy) for the Protection of Human Subjects (56 FR 28003).
The Common Rule (Federal Policy) is also codified at
  7 CFR Part 1c Department of Agriculture
10 CFR Part 745 Department of Energy
14 CFR Part 1230 National Aeronautics and Space Administration
15 CFR Part 27 Department of Commerce
16 CFR Part 1028 Consumer Product Safety Commission
22 CFR Part 225 International Development Cooperation Agency, Agency for International
Development
24 CFR Part 60 Department of Housing and Urban Development
28 CFR Part 46 Department of Justice
32 CFR Part 219 Department of Defense
34 CFR Part 97 Department of Education
38 CFR Part 16 Department of Veterans Affairs
40 CFR Part 26 Environmental Protection Agency
45 CFR Part 690 National Science Foundation
49 CFR Part 11 Department of Transportation
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TITLE 45
CODE OF FEDERAL REGULATIONS
PART 46
PROTECTION OF HUMAN SUBJECTS
* * *
Revised June 18, 1991
Effective August 19, 1991
* * *
Subpart A Federal Policy for the Protection of Human Subjects (Basic DHHS Policy for Protection
of Human Research Subjects)
Source: 56 FR 28003, June 18, 1991.
§46.101 To what does this policy apply?
(a) Except as provided in paragraph (b) of this section, this policy applies to all research involving
human subjects conducted, supported or otherwise subject to regulation by any Federal
Department or Agency which takes appropriate administrative action to make the policy
applicable to such research. This includes research conducted by Federal civilian employees or
military personnel, except that each Department or Agency head may adopt such procedural
modifications as may be appropriate from an administrative standpoint. It also includes research
conducted, supported, or otherwise subject to regulation by the Federal Government outside the
United States.
(1) Research that is conducted or supported by a Federal Department or Agency, whether or not it
is regulated as defined in §46.102(e), must comply with all sections of this policy.
(2) Research that is neither conducted nor supported by a Federal Department or Agency but is
subject to regulation as defined in §46.102(e) must be reviewed and approved, in compliance with
§46.101, §46.102, and §46.107 through §46.117 of this policy, by an Institutional Review Board
(IRB) thatoperates in accordance with the pertinent requirements of this policy.
(b) Unless otherwise required by Department or Agency heads, research activities in which the only
involvement of human subjects will be in one or more of the following categories are exempt
from this policy:1
(1) Research conducted in established or commonly accepted educational settings, involving normal
educational practices, such as (i) research on regular and special education instructional strategies,
or (ii) research on the effectiveness of or the comparison among instructional techniques, curricula,
or classroom management methods.
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(2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement),
survey procedures, interview procedures or observation of public behavior, unless:
(i) information obtained is recorded in such a manner that human subjects can be identified, directly
or through identifiers linked to the subjects; and 
(ii) any disclosure of the human subjects' responses outside the research could reasonably place the
subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing,
employability, or reputation.
(3) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement),
survey procedures, interview procedures, or observation of public behavior that is not exempt under
paragraph (b)(2) of this section, if:
(i) the human subjects are elected or appointed public officials or candidates for public office; or
(ii) Federal statute(s) require(s) without exception that the confidentiality of the personally
identifiable information will be maintained throughout the research and thereafter.
(4) Research involving the collection or study of existing data, documents, records, pathological
specimens, or diagnostic specimens, if these sources are publicly available or if the information is
recorded by the investigator in such a manner that subjects cannot be identified, directly or through
identifiers linked to the subjects.
(5) Research and demonstration projects which are conducted by or subject to the approval of
Department or Agency heads, and which are designed to study, evaluate, or otherwise examine:
(i) Public benefit or service programs; 
(ii) procedures for obtaining benefits or services under those programs; 
(iii) possible changes in or alternatives to those programs or procedures; or 
(iv) possible changes in methods or levels of payment for benefits or services under those programs.
(6) Taste and food quality evaluation and consumer acceptance studies, (i) if wholesome foods
without additives are consumed or (ii) if a food isconsumed that contains a food ingredient at or
below the level and for a use found to be safe, or agricultural chemical or environmental contaminant
at or below the level found to be safe, by the Food and Drug Administration or approved by the
Environmental Protection Agency or the Food Safety and Inspection Service of 
the U.S. Department of Agriculture.
(c) Department or Agency heads retain final judgment as to whether a particular activity is covered
by this policy.
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(d) Department or Agency heads may require that specific research activities or classes of research
activities conducted, supported, or otherwise subject to regulation by the Department or Agency
but not otherwise covered by this policy, comply with some or all of the requirements of this
policy.
(e) Compliance with this policy requires compliance with pertinent Federal laws or regulations
which provide additional protections for human subjects.
(f) This policy does not affect any State or local laws or regulations which may otherwise be
applicable and which provide additional protections for human subjects.
(g) This policy does not affect any foreign laws or regulations which may otherwise be applicable
and which provide additional protections to human subjects of research.
(h) When research covered by this policy takes place in foreign countries, procedures normally
followed in the foreign countries to protect human subjects may differ from those set forth in this
policy. [An example is a foreign institution which complies with guidelines consistent with the
World Medical Assembly Declaration (Declaration of Helsinki amended 1989) issued either by
sovereign states or by an organization whose function for the protection of human research
subjects is internationally recognized.] In these circumstances, if a Department or Agency head
determines that the procedures prescribed by the institution afford protections that are at least
equivalent to those provided in this policy, the Department or Agency head may approve the
substitution of the foreign procedures in lieu of the procedural requirements provided in this
policy. Except when otherwise required by statute, Executive Order, or the Department or
Agency head, notices of these actions as they occur will be published in the Federal Register or
will be otherwise published as provided in Department or Agency procedures.
(i) Unless otherwise required by law, Department or Agency heads may waive the applicability of
some or all of the provisions of this policy to specific research activities or classes or research
activities otherwise covered by this policy. Except when otherwise required by statute or
Executive Order, the Department or Agencyhead shall forward advance notices of these actions
to the Office for Protection from Research Risks, National Institutes of Health, Department of
Health and Human Services (DHHS), and shall also publish them in the Federal Register or in
such other manner as provided in Department or Agency procedures.1
1 Institutions with DHHS-approved assurances on file will abide by provisions of Title 45 CFR Part
46 Subparts A-D. Some of the other departments and agencies have incorporated all provisions of
Title 45 CFR Part 46 into their policies and procedures as well. However, the exemptions at 45 CFR
46.101(b) do not apply to research involving prisoners, fetuses, pregnant women, or human in vitro
fertilization, Subparts B and C. The exemption at 45 CFR 46.101(b)(2), for research involving
survey or interview procedures or observation of public behavior, does not apply to research with
children, Subpart D, except for research involving observations of public behavior when the
investigator(s) do not participate in the activities being observed.
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§46.102 Definitions.
(a)  Department or Agency head means the head of any Federal Department or Agency and any other
officer or employee of any Department or Agency to whom authority has been delegated.
(b) Institution means any public or private entity or Agency (including Federal, State, and other
agencies).
(c)  Legally authorized representative means an individual or judicial or other body authorized under
applicable law to consent on behalf of a prospective subject to the subject's participation in the
procedure(s) involved in the research.
(d) Research means a systematic investigation, including research development, testing and
evaluation, designed to develop or contribute to generalizable knowledge. Activities which meet
this definition constitute research for purposes of this policy, whether or not they are conducted
or supported under a program which is considered research for other purposes. For example,
some demonstration and service programs may include research activities.
(e) Research subject to regulation, and similar terms are intended to encompass those research
activities for which a Federal Department or Agency has specific responsibility for regulating
as a research activity, (for example, Investigational New Drug requirements administered by the
Food and Drug Administration). It does not include research activities which are incidentally
regulated by a Federal Department or Agency solely as part of the Department's or Agency's
broader responsibility to regulate certain types of activities whether research or non-research in
nature (for example, Wage and Hour requirements administered by the Department of Labor).
(f) Human subject means a living individual about whom an investigator (whether professional or
student) conducting research obtains
(1) data through intervention or interaction with the individual, or
(2) identifiable private information.
Intervention includes both physical procedures by which data are gathered (for example,
venipuncture) and manipulations of the subject or the subject's environment that are performed for
research purposes. Interaction includes communication or interpersonal contact between investigator
and subject. Private information includes information about behavior that occurs in a context in
which an individual can reasonably expect that no observation or recording is taking place, and
information which has been provided for specific purposes by an individual and which the individual
can reasonably expect will not be made public (for example, a medical record). Private information
must be individually identifiable (i.e., the identity of the subject is or may readily be ascertained by
the investigator or associated with the information) in order for obtaining the information to
constitute research involving human subjects.
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(g) IRB means an Institutional Review Board established in accord with and for the purposes
expressed in this policy.
(h) IRB approval means the determination of the IRB that the research has been reviewed and may
be conducted at an institution within the constraints set forth by the IRB and by other
institutional and Federal requirements.
(i)  Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the
research are not greater in and of themselves than those ordinarily encountered in daily life or
during the performance of routine physical or psychological examinations or tests.
(j)  Certification means the official notification by the institution to the supporting Department or
Agency, in accordance with the requirements of this policy, that a research project or activity
involving human subjects has been reviewed and approved by an IRB in accordance with an
approved assurance.
§46.103 Assuring compliance with this policy -- research conducted or supported by any Federal
Department or Agency.
(a)  Each institution engaged in research which is covered by this policy and which is conducted or
supported by a Federal Department or Agency shall providewritten assurance satisfactory to the
Department or Agency head that it will comply with the requirements set forth in this policy. In
lieu of requiring submission of an assurance, individual Department or Agency heads shall
accept the existence of a current assurance, appropriate for the research in question, on file with
the Office for Protection from Research Risks, National Institutes Health, DHHS, and approved
for Federalwide use by that office. When the existence of an DHHS-approved assurance is
accepted in lieu of requiring submission of an assurance, reports (except certification) required
by this policy to be made to Department and Agency heads shall also be made to the Office for
Protection from Research Risks, National Institutes of Health, DHHS.
(b) Departments and agencies will conduct or support research covered by this policy only if the
institution has an assurance approved as provided in this section, and only if the institution has
certified to the Department or Agency head that the research has been reviewed and approved
by an IRB provided for in the assurance, and will be subject to continuing review by the IRB.
Assurances applicable to federally supported or conducted research shall at a minimum include:
(1) A statement of principles governing the institution in the discharge of   its responsibilities for
protecting the rights and welfare of human subjects   of research conducted at or sponsored by the
institution, regardless of   whether the research is subject to Federal regulation. This may include an
 appropriate existing code, declaration, or statement of ethical principles, or   a statement formulated
by the institution itself. This requirement does not   preempt provisions of this policy applicable to
Department- or   Agency-supported or regulated research and need not be applicable to any   research
exempted or waived under §46.101 (b) or (I).
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(2) Designation of one or more IRBs established in accordance with the   requirements of this policy,
and for which provisions are made for meeting   space and sufficient staff to support the IRB's
review and recordkeeping duties.
(3) A list of IRB members identified by name; earned degrees; representative   capacity; indications
of experience such as board certifications, licenses, etc., sufficient to describe each member's chief
anticipated contributions to   IRB deliberations; and any employment or other relationship between
each   member and the institution; for example: full-time employee, part-time   employee, member
of governing panel or board, stockholder, paid or unpaid   consultant. Changes in IRB membership
shall be reported to the Department or Agency head, unless in accord with §46.103(a) of this policy,
the existence of   a DHHS-approved assurance is accepted. In this case, change in IRB membership
shall be reported to the Office for Protection from Research Risks, National Institutes of Health,
DHHS.
(4) Written procedures which the IRB will follow (i) for conducting its   initial and continuing
review of research and for reporting its findings and   actions to the investigator and the institution;
(ii) for determining which projects require review more often than annually and which projects need
verification from sources other than the investigators that no material   changes have occurred since
previous IRB review; and (iii) for ensuring prompt reporting to the IRB of proposed changes in a
research activity, and for ensuring that such changes in approved research, during the period for
which IRB approval has already been given, may not be initiated without IRB review and approval
except when necessary to eliminate apparent immediate hazards to the subject.
(5) Written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials,
and the Department or Agency head of (i) any unanticipated problems involving risks to subjects or
others or any serious or continuing noncompliance with this policy or the requirements or
determinations of the IRB; and (ii) any suspension or termination of IRB  approval.
(c) The assurance shall be executed by an individual authorized to act for the institution and to
assume on behalf of the institution the obligations imposed by this policy and shall be filed in
such form and manner as the Department or Agency head prescribes.
(d) The Department or Agency head will evaluate all assurances submitted in accordance with this
policy through such officers and employees of the Department or Agency and such experts or
consultants engaged for this purpose as the Department or Agency head determines to be
appropriate. The Department or Agency head's evaluation will take into consideration the
adequacy of the proposed IRB in light of the anticipated scope of the institution's research
activities and the types of subject populations likely to be involved, the appropriateness of the
proposed initial and continuing review procedures in light of the probable risks, and the size and
complexity of the institution.
(e) On the basis of this evaluation, the Department or Agency head may approve or disapprove the
assurance, or enter into negotiations to develop an approvable one. The Department or Agency
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head may limit the period during which any particular approved assurance or class of approved
assurances shall remain effective or otherwise condition or restrict approval.
(f) Certification is required when the research is supported by a Federal Department or Agency and
not otherwise exempted or waived under §46.101 (b) or 
(i). An institution with an approved assurance shall certify that each application or proposal for
research covered by the assurance and by §46.103 of this policy has been reviewed and approved
by the IRB. Such certification must be submitted with the application or proposal or by such later
date as may be prescribed by the Department or Agency to which the application or proposal is
submitted. Under no condition shall research covered by §46.103 of the policy be supported prior
to receipt of the certification that the research has been reviewed and approved by the IRB.
Institutions without an approved assurance covering the research shall certify within 30 days
after receipt of a request for such a certification from the Department or Agency, that the
application or proposal has been approved by the IRB. If the certification is not submitted within
these time limits, the application or proposal may be returned to the institution.
(Approved by the Office of Management and Budget under Control Number 9999-0020.)
§§46.104--46.106 [Reserved]
§46.107 IRB membership.
(a) Each IRB shall have at least five members, with varying backgrounds to promote complete and
adequate review of research activities commonly conducted by the institution. The IRB shall be
sufficiently qualified through the experience and expertise of its members, and the diversity of
the members, including consideration of race, gender, and cultural backgrounds and sensitivity
to such issues as community attitudes, to promote respect for its advice and counsel in
safeguarding the rights and welfare of human subjects. In addition to possessing the professional
competence necessary to review specific research activities, the IRB shall be able to ascertain
the acceptability of proposed research in terms of institutional commitments and regulations,
applicable law, and standards of professional conduct and practice. The IRB shall therefore
include persons knowledgeable in these areas. If an IRB regularly reviews research that involves
a vulnerable category of subjects, such as children, prisoners, pregnant women, or handicapped
or mentally disabled persons, consideration shall be given to the inclusion of one or more
individuals who are knowledgeable about and experienced in working with these subjects.
(b) Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of men or
entirely of women, including the institution's consideration of qualified persons of both sexes,
so long as no selection is made to the IRB on the basis of gender. No IRB may consist entirely
of members of one profession.
(c) Each IRB shall include at least one member whose primary concerns are in scientific areas and
at least one member whose primary concerns are in nonscientific areas.
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(d) Each IRB shall include at least one member who is not otherwise affiliated with the institution
and who is not part of the immediate family of a person who is affiliated with the institution.
(e)  No IRB may have a member participate in the IRB's initial or continuing review of any project
in which the member has a conflicting interest, except to provide information requested by the
IRB.
(f)  An IRB may, in its discretion, invite individuals with competence in special areas to assist in the
review of issues which require expertise beyond or in addition to that available on the IRB.
These individuals may not vote with the IRB
§46.108 IRB functions and operations.
In order to fulfill the requirements of this policy each IRB shall:
(a) Follow written procedures in the same detail as described in §46.103(b)(4) and to the extent
required by §46.103(b)(5).
(b) Except when an expedited review procedure is used (see §46.110), review proposed research at
convened meetings at which a majority of the members of the IRB are present, including at least
one member whose primary concerns are in nonscientific areas. In order for the research to be
approved, it shall receive the approval of a majority of those members present at the meeting
§46.109 IRB review of research.
(a)  An IRB shall review and have authority to approve, require modifications in (to secure
approval), or disapprove all research activities covered by this policy.
(b) An IRB shall require that information given to subjects as part of informed consent is in
accordance with §46.116. The IRB may require that information, in addition to that specifically
mentioned in §46.116, be given to the subjects when in the IRB's judgment the information
would meaningfully add to the protection of the rights and welfare of subjects.
(c) An IRB shall require documentation of informed consent or may waive documentation in
accordance with §46.117.
(d) An IRB shall notify investigators and the institution in writing of its decision to approve or
disapprove the proposed research activity, or of modifications required to secure IRB approval
of the research activity. If the IRB decides to disapprove a research activity, it shall include in
its written notification a statement of the reasons for its decision and give the investigator an
opportunity to respond in person or in writing.
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(e) An IRB shall conduct continuing review of research covered by this policy at intervals
appropriate to the degree of risk, but not less than once per year, and shall have authority to
observe or have a third party observe the consent process and the research.
(Approved by the Office of Management and Budget under Control Number 9999-0020.)
§46.110 Expedited review procedures for certain kinds of research involving no more than minimal
risk, and for minor changes in approved research.
(a) The Secretary, HHS, has established, and published as a Notice in the Federal Register, a list of
categories of research that may be reviewed by the IRB through an expedited review procedure.
The list will be amended, as appropriate, after consultation with other departments and agencies,
through periodic republication by the Secretary, HHS, in the Federal Register. A copy of the list
is available from the Office for Protection from Research Risks, National Institutes of Health,
DHHS, Bethesda, Maryland 20892.
(b) An IRB may use the expedited review procedure to review either or both of the following:
(1) some or all of the research appearing on the list and found by the reviewer(s) to involve no more
than minimal risk,
(2) minor changes in previously approved research during the period (of one year or less) for which
approval is authorized.
Under an expedited review procedure, the review may be carried out by the IRB chairperson or by
one or more experienced reviewers designated by the chairperson from among members of the IRB.
In reviewing the research, the reviewers may exercise all of the authorities of the IRB except that the
reviewers may not disapprove the research. A research activity may be disapproved only after review
in accordance with the non-expedited procedure set forth in §46.108(b).
(c) Each IRB which uses an expedited review procedure shall adopt a method for keeping all
members advised of research proposals which have been approved under the procedure.
(d) The Department or Agency head may restrict, suspend, terminate, or choose not to authorize an
institution's or IRB's use of the expedited review procedure.
§46.111 Criteria for IRB approval of research.
(a) In order to approve research covered by this policy the IRB shall determine that all of the
following requirements are satisfied:
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(1) Risks to subjects are minimized: (i) by using procedures which are consistent with sound research
design and which do not unnecessarily expose subjects to risk, and (ii) whenever appropriate, by
using procedures already being performed on the subjects for diagnostic or treatment purposes.
(2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the
importance of the knowledge that may reasonably be expected to result. In evaluating risks and
benefits, the IRB should consider only those risks and benefits that may result from the research (as
distinguished from risks and benefits of therapies subjects would receive even if not participating
in the research). The IRB should not consider possible long-range effects of applying knowledge
gained in the research (for example, the possible effects of the research on public policy) as among
those research risks that fall within the purview of its responsibility.
(3) Selection of subjects is equitable. In making this assessment the IRB should take into account
the purposes of the research and the setting in which the research will be conducted and should be
particularly cognizant of the special problems of research involving vulnerable populations, such as
children, prisoners, pregnant women, mentally disable persons, or economically or educationally
disadvantaged persons.
(4) Informed consent will be sought from each prospective subject or the subject's legally authorized
representative, in accordance with, and to the extent required by §46.116.
(5) Informed consent will be appropriately documented, in accordance with, and to the extent
required by §46.117.
(6) When appropriate, the research plan makes adequate provision for monitoring the data collected
to ensure the safety of subjects.
(7) When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain
the confidentiality of data.
(b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such
as children, prisoners, pregnant women, mentally disabled persons, or economically or educationally
disadvantaged persons, additional safeguards have been included in the study to protect the rights
and welfare of these subjects.
§46.112 Review by institution.
Research covered by this policy that has been approved by an IRB may be subject to further
appropriate review and approval or disapproval by officials of the institution. However, those
officials may not approve the research if it has not been approved by an IRB.
§46.113 Suspension or termination of IRB approval of research.
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An IRB shall have authority to suspend or terminate approval of research that is not being conducted
in accordance with the IRB's requirements or that has been associated with unexpected serious harm
to subjects. Any suspension or termination or approval shall include a statement of the reasons for
the IRB's action and shall be reported promptly to the investigator, appropriate 
institutional officials, and the Department or Agency head.
(Approved by the Office of Management and Budget under Control Number 9999-0020.)
§46.114 Cooperative research.
Cooperative research projects are those projects covered by this policy which involve more than one
institution. In the conduct of cooperative research projects, each institution is responsible for
safeguarding the rights and welfare of human subjects and for complying with this policy. With the
approval of the Department or Agency head, an institution participating in a cooperative 
project may enter into a joint review arrangement, rely upon the review of another qualified IRB, or
make similar arrangements for avoiding duplication of effort.
§46.115 IRB records.
(a) An institution, or when appropriate an IRB, shall prepare and maintain adequate documentation
of IRB activities, including the following:
(1) Copies of all research proposals reviewed, scientific evaluations, if any,   that accompany the
proposals, approved sample consent documents, progress reports submitted by investigators, and
reports of injuries to subjects.
(2) Minutes of IRB meetings which shall be in sufficient detail to show attendance at the meetings;
actions taken by the IRB; the vote on these actions including the number of members voting for,
against, and abstaining; the basis for requiring changes in or disapproving research; and a written
summary of the discussion of controverted issues and their resolution.
(3) Records of continuing review activities.
(4) Copies of all correspondence between the IRB and the investigators.
(5) A list of IRB members in the same detail as described in §46.103(b)(3).
(6) Written procedures for the IRB in the same detail as described in §46.103(b)(4) and
§46.103(b)(5).
(7) Statements of significant new findings provided to subjects, as required by §46.116(b)(5).
(b) The records required by this policy shall be retained for at least 3 years, and records relating to
research which is conducted shall be retained for at least 3 years after completion of the research.
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All records shall be accessible for inspection and copying by authorized representatives of the
Department or Agency at reasonable times and in a reasonable manner.
(Approved by the Office of Management and Budget under Control Number 9999-0020.)
§46.116 General requirements for informed consent.
Except as provided elsewhere in this policy, no investigator may involve a human being as a subject
in research covered by this policy unless the investigator has obtained the legally effective informed
consent of the subject or the subject's legally authorized representative. An investigator shall seek
such consent only under circumstances that provide the prospective subject or the representative
sufficient opportunity to consider whether or not to participate and that minimize the possibility of
coercion or undue influence. The information that is given to the subject or the representative shall
be in language understandable to the subject or the representative. No informed consent, whether oral
or written, may include any exculpatory language through which the subject or the representative is
made to waive or appear to waive any 
of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the
institution or its agents from liability for negligence.
(a) Basic elements of informed consent. Except as provided in paragraph (c) or 
(d) of this section, in seeking informed consent the following information shall be provided to each
subject:
(1) a statement that the study involves research, an explanation of the purposes of the research and
the expected duration of the subject's participation, a description of the procedures to be followed,
and identification of any procedures which are experimental;
(2) a description of any reasonably foreseeable risks or discomforts to the subject;
(3) a description of any benefits to the subject or to others which may reasonably be expected from
the research;
(4) a disclosure of appropriate alternative procedures or courses of treatment, if any, that might be
advantageous to the subject;
(5) a statement describing the extent, if any, to which confidentiality of records identifying the
subject will be maintained;
(6) for research involving more than minimal risk, an explanation as to whether any compensation
and an explanation as to whether any medical treatments are available if injury occurs and, if so,
what they consist of, or where further information may be obtained;
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(7) an explanation of whom to contact for answers to pertinent questions about the research and
research subjects' rights, and whom to contact in the event of a research-related injury to the subject;
and
(8) a statement that participation is voluntary, refusal to participate will involve no penalty or loss
of benefits to which the subject is otherwise entitled, and the subject may discontinue participation
at any time without penalty or loss of benefits to which the subject is otherwise entitled.
(b) additional elements of informed consent. When appropriate, one or more of the following
elements of information shall also be provided to each subject:
(1) a statement that the particular treatment or procedure may involve risks to the subject (or to the
embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable;
(2) anticipated circumstances under which the subject's participation may be terminated by the
investigator without regard to the subject's consent;
(3) any additional costs to the subject that may result from participation in the research;
(4) the consequences of a subject's decision to withdraw from the research and procedures for orderly
termination of participation by the subject;
(5) A statement that significant new findings developed during the course of the research which may
relate to the subject's willingness to continue participation will be provided to the subject; and
(6) the approximate number of subjects involved in the study.
(c) An IRB may approve a consent procedure which does not include, or which alters, some or all
of the elements of informed consent set forth above, or waive the requirement to obtain informed
consent provided the IRB finds and documents that:
(1) the research or demonstration project is to be conducted by or subject to the approval of state or
local government officials and is designed to study, evaluate, or otherwise examine: (i) public benefit
or service programs; (ii) procedures for obtaining benefits or services under those programs; (iii)
possible changes in or alternatives to those programs or procedures; or (iv)  possible changes in
methods or levels of payment for benefits or services under those programs; and
(2) the research could not practicably be carried out without the waiver or alteration.
(d) An IRB may approve a consent procedure which does not include, or which alters, some or all
of the elements of informed consent set forth in this section, or waive the requirements to obtain
informed consent provided the IRB finds and documents that:
(1) the research involves no more than minimal risk to the subjects;
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(2) the waiver or alteration will not adversely affect the rights and welfare of the subjects;
(3) the research could not practicably be carried out without the waiver or alteration; and
(4) whenever appropriate, the subjects will be provided with additional pertinent information after
participation.
(e) The informed consent requirements in this policy are not intended to preempt any applicable
Federal, State, or local laws which require additional information to be disclosed in order for
informed consent to be legally effective.
(f) Nothing in this policy is intended to limit the authority of a physician to provide emergency
medical care, to the extent the physician is permitted to do so under applicable Federal, State, or
local law.
(Approved by the Office of Management and Budget under Control Number 9999-0020.)
§46.117 Documentation of informed consent.
(a) Except as provided in paragraph (c) of this section, informed consent shall be documented by the
use of a written consent form approved by the IRB and signed by the subject or the subject's legally
authorized representative. A copy shall be given to the person signing the form.
(b) Except as provided in paragraph (c) of this section, the consent form may be either of the
following:
(1) A written consent document that embodies the elements of informed consent required by
§46.116. This form may be read to the subject or the subject's legally authorized representative, but
in any event, the investigator shall give either the subject or the representative adequate opportunity
to read it before it is signed; or
(2) A short form written consent document stating that the elements of informed consent required
by §46.116 have been presented orally to the subject or the subject's legally authorized
representative. When this method is used, there shall be a witness to the oral presentation. Also, the
IRB shall approve a written summary of what is to be said to the subject or the representative.  Only
the short form itself is to be signed by the subject or the representative. However, the witness shall
sign both the short form and a copy of the summary, and the person actually obtaining consent shall
sign a copy of the summary. A copy of the summary shall be given to the subject or the
representative, in addition to a copy of the short form.
(c) An IRB may waive the requirement for the investigator to obtain a signed consent form for some
or all subjects if it finds either:
Page 50 Miami University
(1) That the only record linking the subject and the research would be the consent document and the
principal risk would be potential harm resulting from a breach of confidentiality. Each subject will
be asked whether the subject wants documentation linking the subject with the research, and the
subject's wishes will govern; or
(2) That the research presents no more than minimal risk of harm to subjects and involves no
procedures for which written consent is normally required outside of the research context. In cases
in which the documentation requirement is waived, the IRB may require the investigator to provide
subjects with a written statement regarding the research.
(Approved by the Office of Management and Budget under Control Number 9999-0020.)
§46.118 Applications and proposals lacking definite plans for involvement of human subjects.
Certain types of applications for grants, cooperative agreements, or contracts are submitted to
departments or agencies with the knowledge that subjects may be involved within the period of
support, but definite plans would not normally be set forth in the application or proposal. These
include activities such as institutional type grants when selection of specific projects is the
institution's responsibility; research training grants in which the activities involving subjects remain
to be selected; and projects in which human subjects' involvement will depend upon completion of
instruments, prior animal studies, or purification of compounds. These applications need not be
reviewed by an IRB before an award may be made. However, except for research exempted or
waived under §46.101 (b) or (i), no human subjects may be involved in any project supported by
these awards until the project has been reviewed and approved by the IRB, as provided in this policy,
and certification submitted, by the institution, to the Department or Agency.
§46.119 Research undertaken without the intention of involving human subjects.
In the event research is undertaken without the intention of involving human subjects, but it is later
proposed to involve human subjects in the research, the research shall first be reviewed and approved
by an IRB, as provided in this policy, a certification submitted, by the institution, to the Department
or Agency, and final approval given to the proposed change by the Department or 
Agency.
§46.120 Evaluation and disposition of applications and proposals for research to be conducted or
supported by a Federal Department or Agency.
(a) The Department or Agency head will evaluate all applications and proposals involving human
subjects submitted to the Department or Agency through such officers and employees of the
Department or Agency and such experts and consultants as the Department or Agency head
determines to be appropriate. This evaluation will take into consideration the risks to the subjects,
the adequacy of protection against these risks, the potential benefits of the research to the subjects
and others, and the importance of the knowledge gained or to be gained.
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(b) On the basis of this evaluation, the Department or Agency head may approve or disapprove the
application or proposal, or enter into negotiations to develop an approvable one.
§46.121 [Reserved]
§46.122 Use of Federal funds.
Federal funds administered by a Department or Agency may not be expended for research involving
human subjects unless the requirements of this policy have been satisfied.
§46.123 Early termination of research support: Evaluation of applications and proposals.
(a) The Department or Agency head may require that Department or Agency support for any project
be terminated or suspended in the manner prescribed in applicable program requirements, when the
Department or Agency head finds an institution has materially failed to comply with the terms of this
policy.
(b) In making decisions about supporting or approving applications or proposals covered by this
policy the Department or Agency head may take into account, in addition to all other eligibility
requirements and program criteria, factors such as whether the applicant has been subject to a
termination or suspension under paragraph (a) of this section and whether the applicant or the person
or persons who would direct or has/have directed the scientific and technical aspects of an activity
has/have, in the judgment of the Department or Agency head, materially failed to discharge
responsibility for the protection of the rights and welfare of human subjects (whether or not the
research was subject to Federal regulation).
§46.124 Conditions.
With respect to any research project or any class of research projects the Department or Agency head
may impose additional conditions prior to or at the time of approval when in the judgment of the
Department or Agency head additional conditions are necessary for the protection of human subjects.
